Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: a review

Pavan, S R; Prabhu, Ashwini

doi:10.1007/s10853-022-07649-z

Cited by 15 publications

(6 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin formulations including polymeric nanoparticles, micelles, dendrimers, and liposomes have a greater chance of delivering persistent cisplatin to the growth in reaction to alterations in the tumor’s microenvironment. 223–227…”

Section: Introductionmentioning

confidence: 99%

A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

Sadeghi,

Kiaei,

Boush

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Adenocarcinoma of the lung is the most common type of lung cancer, and it is characterized by distinct cellular and molecular features. It occurs when abnormal lung cells multiply out of control and form a tumor in the outer region of the lungs. Adenocarcinoma of the lung is a serious and life-threatening condition that requires effective and timely management to improve the survival and quality of life of the patients. One of the challenges in this cancer treatment is finding the optimal combination of drugs that can target the genes or proteins that are involved in the disease process. Method: In this article, we propose a novel method to recommend combinations of trending drugs to target its associated proteins/genes, using a Graph Neural Network (GNN) under the RAIN protocol. The RAIN protocol is a three-step framework that consists of: 1) Applying graph neural networks to recommend drug combinations by passing messages between trending drugs for managing disease and genes that act as potential targets for disease; 2) Retrieving relevant articles with clinical trials that include those proposed drugs in previous step using Natural Language Processing (NLP); 3) Analyzing the network meta-analysis to measure the comparative efficacy of the drug combinations. Result: We applied our method to a dataset of nodes and edges that represent the network, where each node is a drug or a gene, and each edge is a p-value between them. We found that the graph neural network recommends combining Gefitinib, Paclitaxel, and Icotinib as the most effective drug combination to target this cancer associated proteins/genes. We reviewed the clinical trials and expert opinions on these medications and found that they support our claim. The network meta-analysis also confirmed the effectiveness of these drugs on associated genes. Conclusion: Our method is a novel and promising approach to recommend trending drugs combination to target cancer associated proteins/genes, using graph neural networks under the RAIN protocol. It can help clinicians and researchers to find the best treatment options for patients, and also provide insights into the underlying mechanisms of the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

Sadeghi,

Kiaei,

Boush

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Although there is extensive literature on the mono- and bidentate coordination of cisplatin in different drug carriers (e.g., in linear and non-linear polymers) [ 21 , 23 , 24 ], the study of the monodentate coordination of cisplatin in dendrimers via carboxylic acid/carboxylate terminal groups and its impact on the cells (e.g., in the cytotoxicity) remains to be performed [ 12 , 25 ]. In line with our team’s expertise in the use of dendrimers for biomedical applications [ 26 , 27 , 28 , 29 , 30 , 31 ], the goal of this study was to, for the first time, assess the effect of the coordination mode of the ligand/metal and the generation of the dendrimer (number of metal fragments it carries) on the delivery of cisplatin to cancer cells using anionic poly(amidoamine) (PAMAM) dendrimers, with carboxylate groups at their periphery.…”

Section: Introductionmentioning

confidence: 99%

Biological Effects in Cancer Cells of Mono- and Bidentate Conjugation of Cisplatin on PAMAM Dendrimers: A Comparative Study

et al. 2023

View full text Add to dashboard Cite

Cisplatin (cis-diamminedichloroplatinum(II)) is a potent chemotherapeutic agent commonly used to treat cancer. However, its use also leads to serious side effects, such as nephrotoxicity, ototoxicity, and cardiotoxicity, which limit the dose that can be safely administered to patients. To minimize these problems, dendrimers may be used as carriers for cisplatin through the coordination of their terminal functional groups to platinum. Here, cisplatin was conjugated to half-generation anionic PAMAM dendrimers in mono- and bidentate forms, and their biological effects were assessed in vitro. After preparation and characterization of the metallodendrimers, their cytotoxicity was evaluated against several cancer cell lines (A2780, A2780cisR, MCF-7, and CACO-2 cells) and a non-cancer cell line (BJ cells). The results showed that all the metallodendrimers were cytotoxic and that the cytotoxicity level depended on the cell line and the type of coordination mode (mono- or bidentate). Although, in this study, a correlation between dendrimer generation (number of carried metallic fragments) and cytotoxicity could not be completely established, the monodentate coordination form of cisplatin resulted in lower IC50 values, thus revealing a more accessible cisplatin release from the dendritic scaffold. Moreover, most of the metallodendrimers were more potent than the cisplatin, especially for the A2780 and A2780cisR cell lines, which showed higher selectivity than for non-cancer cells (BJ cells). The monodentate G0.5COO(Pt(NH3)2Cl)8 and G2.5COO(Pt(NH3)2Cl)32 metallodendrimers, as well as the bidentate G2.5COO(Pt(NH3)2)16 metallodendrimer, were even more active towards the cisplatin-resistant cell line (A2780cisR cells) than the correspondent cisplatin-sensitive one (A2780 cells). Finally, the effect of the metallodendrimers on the hemolysis of human erythrocytes was neglectable, and metallodendrimers’ interaction with calf thymus DNA seemed to be stronger than that of free cisplatin.

show abstract

“…9,10 Commonly used capping agents include surfactants, polymers, and proteins. [11][12][13][14] The use of dissolvable plant extracts has revealed promising potential in the eco-friendly synthesis of nanoparticles (NPs) owing to their dual action as both reducing and capping agents. [15][16][17][18] These extracts are composed of a diverse array of natural compounds, including avonoids, phenolic acids, and terpenoids, all of which exhibit notable reducing and capping properties.…”

Section: Introductionmentioning

confidence: 99%

Phytofabrication of silver nanoparticles using Averrhoa bilimbi leaf extract for anticancer activity

2023

View full text Add to dashboard Cite

show abstract

Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: a review

Cited by 15 publications

References 134 publications

A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

Biological Effects in Cancer Cells of Mono- and Bidentate Conjugation of Cisplatin on PAMAM Dendrimers: A Comparative Study

Phytofabrication of silver nanoparticles using Averrhoa bilimbi leaf extract for anticancer activity

Contact Info

Product

Resources

About